<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medical  Diagnosis</journal-title></journal-title-group><issn pub-type="epub">2164-540X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/MD.2021.112012</article-id><article-id pub-id-type="publisher-id">MD-41501</article-id><article-categories><subj-group subj-group-type="heading"><subject>MD20210200000_27242821.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  补肾祛毒丸对维持性血液透析患者微炎症状态影响的临床研究
  Clinical Study on the Effect of BuShen QuDu Pill on Microinflammatory State in Patients with Maintenance Hemodialysis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>强</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>唐</surname><given-names>娟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>林</surname><given-names>武</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>鹏声</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>何</surname><given-names>东娟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>晓凌</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>福建中医药大学附属第二人民医院肾病科，福建 福州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>12</day><month>04</month><year>2021</year></pub-date><volume>11</volume><issue>02</issue><fpage>73</fpage><lpage>78</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：观察补肾祛毒丸对维持性血液透析患者微炎症状态相关因子超敏C反应蛋白(hypersensitive C-reactive protein, hs-CRP)、白细胞介素-6 (interleukin-6, IL-6)、肿瘤坏死因子-α (tumor necrosis factor alpha, TNF-α)白细胞介素-10 (interleukin-10, IL-10)的影响，客观评价其有效性，方法：将48例中医辨证为脾肾气虚的维持性血液透析患者随机分为治疗组和对照组，每组24例。对照组采用血液透析和常规治疗；治疗组在对照组的基础上加用补肾祛毒丸(院内制剂，闽药制字Z05104024)口服治疗，每次5 g，每天3次。两组患者均在治疗前及治疗3个月后检测指标。结果：治疗后治疗组的hs-CRP、IL-6、TNF-α水平与对照组比较，治疗组明显降低，差异有统计学意义(P &lt; 0.05)。与对照组比较，治疗组治疗后IL-10升高，差异有统计学意义(P &lt; 0.05)。结论：补肾祛毒丸可影响维持性血液透析患者微炎症因子水平，改善患者的微炎症状态。
   Objective: To observe the effects of BuShen QuDu Pill on hypersensitive C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α) and interleukin-10 (IL-10) related factors of microinflammatory state in maintenance hemodialysis patients, and to objectively evaluate its effectiveness. Methods: 48 patients with spleen and kidney qi deficiency were randomly divided into treatment group and control group, 24 cases in each group. The control group received hemodialysis and routine treatment. On the basis of control group, the treatment group was addi-tively treated with Bushen Qudu Pilll (hospital preparation, Minyao system word Z05104024) for oral treatment, 5 g each time, 3 times a day. The indexes of patients in both groups were detected before and 3 months after treatment. Results: After treatment, the levels of hs-CRP, IL-6 and TNF-α in the treatment group were significantly lower than those in the control group, with statistical significance (P &lt; 0.05). Compared with the control group, IL-10 increased in the treatment group after treatment, and the difference was statistically significant (P &lt; 0.05). Conclusion: Bushen Qudu Pilll can affect the level of microinflammatory factors and improve the microinflammatory state in patients with maintenance hemodialysis.
 
</p></abstract><kwd-group><kwd>补肾祛毒丸，血液透析，微炎症, BuShen QuDu Pill</kwd><kwd> Hemodialysis</kwd><kwd> Microinflammation</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：观察补肾祛毒丸对维持性血液透析患者微炎症状态相关因子超敏C反应蛋白(hypersensitive C-reactive protein, hs-CRP)、白细胞介素-6 (interleukin-6, IL-6)、肿瘤坏死因子-α (tumor necrosis factor alpha, TNF-α)白细胞介素-10 (interleukin-10, IL-10)的影响，客观评价其有效性，方法：将48例中医辨证为脾肾气虚的维持性血液透析患者随机分为治疗组和对照组，每组24例。对照组采用血液透析和常规治疗；治疗组在对照组的基础上加用补肾祛毒丸(院内制剂，闽药制字Z05104024)口服治疗，每次5 g，每天3次。两组患者均在治疗前及治疗3个月后检测指标。结果：治疗后治疗组的hs-CRP、IL-6、TNF-α水平与对照组比较，治疗组明显降低，差异有统计学意义(P &lt; 0.05)。与对照组比较，治疗组治疗后IL-10升高，差异有统计学意义(P &lt; 0.05)。结论：补肾祛毒丸可影响维持性血液透析患者微炎症因子水平，改善患者的微炎症状态。</p></sec><sec id="s2"><title>关键词</title><p>补肾祛毒丸，血液透析，微炎症</p></sec><sec id="s3"><title>Clinical Study on the Effect of BuShen QuDu Pill on Microinflammatory State in Patients with Maintenance Hemodialysis</title><p>Qiang Wu, Juan Tang, Wu Lin, Pengsheng Zhang, Dongjuan He, Xiaoling Yang</p><p>Department of Nephrology, The Second People’s Hospital Affiliated to Fujian University of Chinese Medicine, Fuzhou Fujian</p><p>Received: Feb. 18<sup>th</sup>, 2021; accepted: Apr. 2<sup>nd</sup>, 2021; published: Apr. 12<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/1-2170288x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To observe the effects of BuShen QuDu Pill on hypersensitive C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α) and interleukin-10 (IL-10) related factors of microinflammatory state in maintenance hemodialysis patients, and to objectively evaluate its effectiveness. Methods: 48 patients with spleen and kidney qi deficiency were randomly divided into treatment group and control group, 24 cases in each group. The control group received hemodialysis and routine treatment. On the basis of control group, the treatment group was additively treated with Bushen Qudu Pilll (hospital preparation, Minyao system word Z05104024) for oral treatment, 5 g each time, 3 times a day. The indexes of patients in both groups were detected before and 3 months after treatment. Results: After treatment, the levels of hs-CRP, IL-6 and TNF-α in the treatment group were significantly lower than those in the control group, with statistical significance (P &lt; 0.05). Compared with the control group, IL-10 increased in the treatment group after treatment, and the difference was statistically significant (P &lt; 0.05). Conclusion: Bushen Qudu Pilll can affect the level of microinflammatory factors and improve the microinflammatory state in patients with maintenance hemodialysis.</p><p>Keywords:BuShen QuDu Pill, Hemodialysis, Microinflammation</p><disp-formula id="hanspub.41501-formula3"><graphic xlink:href="//html.hanspub.org/file/1-2170288x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-2170288x7_hanspub.png" /> <img src="//html.hanspub.org/file/1-2170288x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>多项研究表明维持性血液透析(MHD)患者普遍存在微炎症状态和氧化应激状态，持续微炎症状态是引起营养不良和动脉粥样硬化的重要因素，可严重影响MHD患者的生活质量，并与维持性血液透析患者心脑血管事件的高发生率、高死亡率密切相关。目前对微炎症状态的治疗还不十分成熟。我们前期临床研究证实补肾祛毒汤可以降低慢性肾衰患者CRP水平，动物实验研究则表明补肾祛毒汤治疗后肾衰大鼠反映微炎症状态的指标改善。本研究对比观察了补肾祛毒丸对脾肾气虚型(MHD)患者微炎症指标的影响，现报道如下。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>选择2015年05月~2018年05月在福建中医药大学附属第二人民医院血液净化科行维持性血液透析治疗的患者48例。入组患者均签署知情同意书，按随机数字表法分为2组，治疗组24例，男15例，女9例；年龄24~78岁，平均(56.30 &#177; 12.37)岁；平均透析时间(36.53 &#177; 10.34)月；慢性肾小球肾炎14例，糖尿病肾病6例，高血压肾病3例，多囊肾1例。对照组24例，男16例，女8例；年龄25~76岁，平均(53.35 &#177; 14.23)岁；平均透析时间(36.54 &#177; 11.23)月；慢性肾小球肾炎12例，糖尿病肾病7例，高血压肾病4例，多囊肾1例。2组一般资料经统计学处理，差异均无显著性意义(P &gt; 0.05)，具有可比性。</p></sec><sec id="s6_2"><title>2.2. 纳入及排除标准</title><p>1) 纳入标准① 符合尿毒症诊断和脾肾气虚辨证分型标准；② 规律透析 ≥ 3月，每周透析时间 ≥ 8 h，单室Kt/V (spKt/V) ≥ 1.2；③ 血管通路为自体动静脉内瘘；④ 所有患者均病情稳定，近3月无出血及输血史；⑤ 年龄18~80岁；⑥ 经医院伦理委员会批准，患者知情同意。2) 排除标准：① 小于18岁，大于80岁；② 感染、慢性肝病、心绞痛及心力衰竭、自身免疫病及恶性肿瘤、使用免疫抑制剂，使用可能影响炎症状态的其他药物；③ 不能达到最基本透析量(每周透析次数少于2次或透析时间少于8小时)的患者；④ 拒绝参加该临床试验者；⑤ 对补肾祛毒丸过敏者；⑥ 有出血或出血倾向者；⑦ 妊娠或哺乳期妇女；⑧ 同时使用同类中药者；⑨ 精神病患者。</p></sec><sec id="s6_3"><title>2.3. 治疗方法</title><p>两组患者血液透析均使用4008-B血液透析机(德国Fresenius公司)行常规血液透析，透析器为尼普洛150G，膜面积1.5 m<sup>2</sup> (日本)，透析管路和穿刺针为同一品牌同一规格，均为一次性使用。使用标准碳酸氢盐透析，透析液为普通透析液，流量500 ml/min，血流量范围200~260 ml/min，每次透析4 h，透析通路为自体动静脉内瘘，抗凝方式为低分子肝素。透析操作严格按照卫生部血液净化标准操作规程(2010版)规定进行。</p><p>对照组：规范血液透析教育、饮食水分摄入指导、控制血压、补充促红素、补充活性维生素D3、叶酸、铁剂、左卡尼汀等常规治疗。</p><p>治疗组：其他方案同对照组，同时予补肾祛毒丸(院内制剂，闽药制字Z05104024)，适量温开水吞服，每次5 g，每日3次(如大便次数大于3次可减量)，餐后服。观察3个月。</p></sec><sec id="s6_4"><title>2.4. 观察指标</title><p>观察治疗前后血清超敏C反应蛋白(hs-CRP)、白细胞介素6 (IL-6)、白细胞介素10 (IL-10)、肿瘤坏死因子α (TNF-α)浓度，试剂盒购自美国R&amp;D公司。雅培CI16200全自动生化免疫分析仪检测血清白蛋白(ALB)、血尿素氮(BUN)、血肌酐(SCr)，美国贝克曼HAM全自动血常规分析仪检测血红蛋白(Hb)。治疗前后均检测ALT、AST、血常规、大便常规+OB、心电图；定期监测血压；观察两组患者的不良反应发生情况。</p></sec><sec id="s6_5"><title>2.5. 统计方法</title><p>采用SPSS26.0统计软件进行统计分析。计量资料均用(x &#177; s)表示，组间比较采用独立样本t检验，治疗前后比较采用配对t检验。以P &lt; 0.05作为差异有统计学意义。</p></sec><sec id="s6_6"><title>2.6. 结果</title><sec id="s6_6_1"><title>2.6.1. 两组维持性血液透析患者hs-CRP、IL-6、TNF-α、IL-10水平比较</title><p>经过治疗后，治疗组hs-CRP、IL-6、TNF-α水平较对照组明显降低(P &lt; 0.05)，提示治疗组对微炎症促进指标的控制较对照组明显；IL-10水平较对照组明显升高(P &lt; 0.05)，提示治疗组对微炎症抑制指标的提升较对照组明显。见下表1。</p></sec><sec id="s6_6_2"><title>2.6.2. 安全性评价</title><p>两组患者在受试过程中生命征较平稳，受试前后血常规、大便常规 + OB、肝功能及心电图等安全性指标均无明显改变。治疗组有4例患者大便次数每日超过3次，2例轻度腹泻经适当减量后均继续完成试验，未见严重不良反应及毒副作用发生。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of hs-CRP, IL-6, TNF-α and IL-10 levels between the two groups of maintenance hemodialysis patients (x &#177; s</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >时间</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >hs-CRP (mg/L)</th><th align="center" valign="middle" >IL-6 (pg/ml)</th><th align="center" valign="middle" >TNF-α (μg/L)</th><th align="center" valign="middle" >IL-10 (pg/ml)</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >对照组</td><td align="center" valign="middle" >研究前</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >5.42 &#177; 2.01</td><td align="center" valign="middle" >1.79 &#177; 0.46</td><td align="center" valign="middle" >61.72 &#177; 9.16</td><td align="center" valign="middle" >1.86 &#177; 0.21</td></tr><tr><td align="center" valign="middle" >研究后</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >5.23 &#177; 1.97</td><td align="center" valign="middle" >1.64 &#177; 0.23</td><td align="center" valign="middle" >62.14 &#177; 7.98</td><td align="center" valign="middle" >1.91 &#177; 0.24</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >治疗组</td><td align="center" valign="middle" >研究前</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >5.36 &#177; 1.72</td><td align="center" valign="middle" >1.81 &#177; 0.29</td><td align="center" valign="middle" >62.49 &#177; 8.73</td><td align="center" valign="middle" >1.81 &#177; 0.32</td></tr><tr><td align="center" valign="middle" >研究后</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >3.49 &#177; 1.03<sup>*</sup></td><td align="center" valign="middle" >1.08 &#177; 0.27<sup>*</sup></td><td align="center" valign="middle" >40.27 &#177; 8.13<sup>*</sup></td><td align="center" valign="middle" >2.63 &#177; 0.16<sup>*</sup></td></tr></tbody></table></table-wrap><p>表1. 两组维持性血液透析患者hs-CRP、IL-6、TNF-α、IL-10水平比较(x &#177; s)</p><p>注：与对照组研究后比较<sup>*</sup>P &lt; 0.05。</p></sec></sec></sec><sec id="s7"><title>3. 讨论</title><p>微炎症状态是指一种非微生物感染引起的、低强度、慢性进展性、非显性炎症状态，表现为全身循环炎症标志蛋白及炎性细胞因子轻度持续增高，导致患者出现各种并发症的非显性炎症状态，具有持续及相对隐匿性，与多种进行性炎症疾病相关。2000年Schomig等提出关于“微炎症状态”的概念认为，维持性血液透析患者体内存在“微炎症状态”：慢性肾功能衰竭患者因种种原因普遍存在慢性炎症反应，其主要表现为炎性因子如白介素-6 (IL-6)、白介素-1 (IL-1)、白介素-10 (IL-10)、肿瘤坏死因子-α (TNF-α)，及急性时相蛋白C-反应蛋白(C-reactive protein, CRP)、血清淀粉样蛋白(SAA)等指标的持续轻度升高 [<xref ref-type="bibr" rid="hanspub.41501-ref1">1</xref>]。</p><p>维持性血液透析(MHD)患者因其长期血液透析，除慢性肾功能衰竭患者存在的因素外，有其特有的因素：因有一定生物不相容性的透析膜接触活化补体并刺激炎性细胞因子转录和表达，在换用生物相容性较好的滤过膜后，患者的炎性反应有所改善；透析液中的内毒素和/或细菌碎片的污染，动静脉内瘘和/或血管内留置导管处反复微量细菌入侵，穿刺激活体内单核–巨噬细胞，晚期糖基化产物和脂质氧化产物的蓄积，酸中毒、透析不充分、肾功能衰竭对而中小分子毒素、炎性因子清除减少而持续蓄积体内，故而较未透析者微炎症状态发生的程度为重，上述指标亦显著升高 [<xref ref-type="bibr" rid="hanspub.41501-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.41501-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.41501-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.41501-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.41501-ref6">6</xref>]。</p><p>大量研究证明，微炎症是微观层面上通过检查血液中的相关物质而确定的，其本质是免疫性炎症，它是MHD患者普遍存在的现象 [<xref ref-type="bibr" rid="hanspub.41501-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.41501-ref8">8</xref>]，造成MHD患者出现贫血、营养不良、动脉粥样样硬化等心血管并发症加剧，影响呼吸功能、动静脉内瘘存活，加重皮肤瘙痒，严重影响MHD患者的生活质量，并与维持性血液透析患者心脑血管事件的高发生率、高死亡率密切相关，因此减少微炎症状态被视为预防并发症的关键 [<xref ref-type="bibr" rid="hanspub.41501-ref9">9</xref>]。</p><p>MHD属于中医学“水肿、关格、虚劳”等病证范畴，脾肾气虚证是其常见证型，临床上主要表现为倦怠乏力、气短懒言、食少纳呆、腰酸膝软等。有观点认为，此阶段基本病机为脾肾虚衰、气虚血瘀、浊毒内蕴、肾脏衰败、脾土失运、无力运化水谷、化生气血，久则湿瘀内生、阻滞气机、浊毒内蕴，气虚湿滞、血瘀浊毒等病因导致微炎症状态的产生，又作为病理产物使虚者更虚，实者更实，导致病情缠绵难愈，最终出现营养不良贫血心脑血管事件等并发症 [<xref ref-type="bibr" rid="hanspub.41501-ref10">10</xref>]。</p><p>近年来中医药针对MHD患者微炎症状态的研究有一定进展。钱宏利等研究证明，以益气健脾、活血利湿药为主要组成的护肾清浊方能显著降低MHD患者的微炎症因子hs-CRP、IL-6、TNF-α水平，一定程度上改善患者的微炎症状态 [<xref ref-type="bibr" rid="hanspub.41501-ref11">11</xref>]。卞书森等研究认为以益肾健脾、化瘀泄浊药为组成的三黄益肾胶囊和补充维生素E均可在一定程度上改善患者体内炎症指标，但服用三黄益肾胶囊较补充维生素E可明显升高ALb、Hb水平 [<xref ref-type="bibr" rid="hanspub.41501-ref10">10</xref>]。苏保林等研究认为尿毒清胶囊可以改善MHD患者微炎症状态，改善贫血 [<xref ref-type="bibr" rid="hanspub.41501-ref12">12</xref>]。王福荣等通过临床研究观察补肾排毒颗粒对维持性血液透析患者微炎症状态及贫血的影响，结果显示治疗后hs-CRP水平明显下降；Hb水平及Hct明显升高，EPO/Hct比值明显下降，且治疗时间越长变化越明显，提示该方对MHD患者微炎症状态及贫血有明显改善作用 [<xref ref-type="bibr" rid="hanspub.41501-ref13">13</xref>]。</p><p>另外我们前期研究证实：临床研究结果显示，慢性肾衰患者CRP水平明显升高，经过补肾祛毒汤治疗后均有明显降低；动物实验研究则表明，补肾祛毒汤治疗后肾衰大鼠血清CRP、TNF-α、IL-6水平亦有显著降低，IL-10水平升高，并较尿毒清治疗组更为显著 [<xref ref-type="bibr" rid="hanspub.41501-ref14">14</xref>]。</p><p>中医并无“炎症、微炎症”病名，但根据其表现可归为中医“湿热、湿浊、湿毒、瘀血”等。CRF久病，脾肾气血阴阳虚衰，脾失健运、肾失气化，水湿痰浊等标实内留；久病必瘀，瘀血、癥瘕内蕴；虚实相互加重而虚、浊、瘀、毒更著。补肾祛毒丸系福建省名中医魏仲南教授根据长期临床治疗肾衰竭的经验研制的院内制剂(闽药制字Z05104024)，组成成分：寄生、生地、山茱萸、党参、黄芪、茯苓、北柴胡、土茯苓、生大黄、当归、丹参、牛膝、醋鳖甲、炮山甲、三七粉。该方能达到健脾补肾、活血化瘀、软坚散结等功效，切中脾肾气虚型MHD患者的中医病机、治疗理论，在补益基础上加以驱邪，同时有祛瘀消癥之妙。同时方中部分药物已被证实能够抗炎症，如黄芪减轻氧自由基损伤、增加超氧化物歧化酶活性、增强细胞免疫功能、提高机体非特异性免疫力的作用,大黄具有清除氧自由基、抗菌消炎、调节免疫、拮抗炎性细胞因子等作用 [<xref ref-type="bibr" rid="hanspub.41501-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.41501-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.41501-ref17">17</xref>]。</p><p>本研究结果表明，采用补肾祛毒丸能改善维持性血液透析患者的微炎症状态，降低了治疗组患者 hs-CRP、IL-6、TNF-α水平，升高IL-10水平，提示可以改善患者微炎症状态，且丸剂不引起容量负荷增加，利于坚持服用，依从性好。因此针对脾肾气虚型的MHD患者补肾祛毒丸有一定的临床使用价值。但因研究过程中制剂停产等原因完成例数偏少，有待今后扩大样本量。</p></sec><sec id="s8"><title>基金项目</title><p>福建省卫生厅中医药科技计划项目(wzsb201310)。</p></sec><sec id="s9"><title>文章引用</title><p>吴 强,唐 娟,林 武,张鹏声,何东娟,杨晓凌. 补肾祛毒丸对维持性血液透析患者微炎症状态影响的临床研究Clinical Study on the Effect of BuShen QuDu Pill on Microinflammatory State in Patients with Maintenance Hemodialysis[J]. 医学诊断, 2021, 11(02): 73-78. https://doi.org/10.12677/MD.2021.112012</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41501-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Schomin, M., Eisenhardt, A. and Ritz, E. (2000) The Microinflammatory State of Uremia. Blood Purification, 18, 327-332. &lt;br&gt;https://doi.org/10.1159/000014457</mixed-citation></ref><ref id="hanspub.41501-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">宋洁, 李辉. 维持性血液透析患者微炎症状态临床研究现状[J]. 武警医学院学报, 2010, 19(8): 669-673.</mixed-citation></ref><ref id="hanspub.41501-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">陈娟娟. 维持性血液透析患者微炎症的防治[J]. 中国医药科学, 2013, 3(2): 38-39.</mixed-citation></ref><ref id="hanspub.41501-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Pecoits-Filho, R., Goncalves, S., Barberato, S.H., et al. (2004) Impact of Residual Renal Func-tion on Volume Status in Chronic Renal Failure. Blood Purification, 22, 285-292. &lt;br&gt;https://doi.org/10.1159/000078699</mixed-citation></ref><ref id="hanspub.41501-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">姚强, 钱家麒. 维持性透析患者体内的炎症状态[J]. 肾脏病透析肾移植杂志, 2005, 14(2): 177-180.</mixed-citation></ref><ref id="hanspub.41501-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">谢明. 不同透析膜对维持性血液透析患者微炎症状态的影响[J]. 内科急危重症杂志, 2015, 21(6): 450-451.</mixed-citation></ref><ref id="hanspub.41501-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">李红微, 刘云霞. 不同血液净化方式对尿毒症患者血清C反应蛋白、白介素-6、血红蛋白及血浆白蛋白水平的影响[J]. 中国当代医药, 2016, 23(1): 71-73.</mixed-citation></ref><ref id="hanspub.41501-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Beberashvili, I., Sinuani, I., Azar, A., et al. (2015) Serum Uric Acid as a Clinically Useful Nutritional Marker and Predictor of Outcome in Maintenance Hemodialysis Patients. Nutrition, 31, 138-147.  
&lt;br&gt;https://doi.org/10.1016/j.nut.2014.06.012</mixed-citation></ref><ref id="hanspub.41501-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">陶静, 孙伟. 维持性血液透析患者与微炎症反应[J]. 肾脏病与透析移植杂志, 2011, 20(2): 176-180.</mixed-citation></ref><ref id="hanspub.41501-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">卞书森, 庄克生, 张福港, 等. 三黄益肾胶囊对维持性血液透析患者微炎症状态的影响[J]. 新中医, 2011, 43(12): 49-50.</mixed-citation></ref><ref id="hanspub.41501-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">钱宏利, 张国胜, 许路军, 等. 护肾清浊方对维持性血液透析患者微炎症因子hs-CRP、IL-6、TNF-α的影响[J]. 中医学报, 2018, 33(3): 468-472.</mixed-citation></ref><ref id="hanspub.41501-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">苏保林, 李敬. 尿毒清胶囊对维持性血液透析患者微炎症状态的影响[J]. 中国中西医结合肾病杂志, 2011, 12(10): 905-906.</mixed-citation></ref><ref id="hanspub.41501-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">王福荣, 王丽华, 李平海, 等. 补肾排毒颗粒对维持性血液透析患者微炎症状态及贫血影响[J]. 中国中西医结合杂志, 2015, 16(12): 1072-1074.</mixed-citation></ref><ref id="hanspub.41501-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">杜锐格. 补肾祛毒汤治疗慢性肾功能衰竭临床与实验研究[D]: [硕士学位论文]. 福州: 福建中医药大学, 2010.</mixed-citation></ref><ref id="hanspub.41501-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">金劲松, 高鸣, 马琼英, 等. 黄芪对MMS损伤乳鼠心肌细胞影响的研究[J]. 中国中西医结合肾病杂志, 2002, 3(1): 16-17.</mixed-citation></ref><ref id="hanspub.41501-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">曲晓璐, 张绪生. 黄芪对维持性血液透析患者细胞免疫影响的观察[J]. 中国中西医结合肾病杂志, 2000, 1(3): 170.</mixed-citation></ref><ref id="hanspub.41501-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">李富岐, 霍静琪, 王长江, 等. 大黄对维持性血液透析患者微炎症状态的影响[J]. 中国血液净化, 2006, 5(2): 101-103.</mixed-citation></ref></ref-list></back></article>